VitaSpring Biomedical Co. Ltd
VitaSpring Biomedical Co. Ltd., a development-stage biomedical company, engages in the research, development, and commercialization of wellness and healthy lifestyle products. The company focuses on the development of cell-based medical technologies for use in regenerative medicine, preventive health care, beauty, and anti-aging applications. It is also involved in the development of cell medicin… Read more
VitaSpring Biomedical Co. Ltd (VSBC) - Total Assets
Latest total assets as of October 2022: $2.44 Million USD
Based on the latest financial reports, VitaSpring Biomedical Co. Ltd (VSBC) holds total assets worth $2.44 Million USD as of October 2022.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
VitaSpring Biomedical Co. Ltd - Total Assets Trend (2017–2026)
This chart illustrates how VitaSpring Biomedical Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
VitaSpring Biomedical Co. Ltd - Asset Composition Analysis
Current Asset Composition (January 2026)
VitaSpring Biomedical Co. Ltd's total assets of $2.44 Million consist of 57.1% current assets and 42.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.9% |
| Accounts Receivable | $380.00K | 49.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2026)
This chart illustrates how VitaSpring Biomedical Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: VitaSpring Biomedical Co. Ltd's current assets represent 57.1% of total assets in 2026, a decrease from 100.0% in 2017.
- Cash Position: Cash and equivalents constituted 3.9% of total assets in 2026, down from 12.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 49.6% of total assets.
VitaSpring Biomedical Co. Ltd Competitors by Total Assets
Key competitors of VitaSpring Biomedical Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
VitaSpring Biomedical Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - VitaSpring Biomedical Co. Ltd generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - VitaSpring Biomedical Co. Ltd is currently not profitable relative to its asset base.
VitaSpring Biomedical Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.33 | 1.92 | 0.81 |
| Quick Ratio | 8.59 | 0.80 | 0.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.58 Million | $ 249.42K | $ -1.51K |
VitaSpring Biomedical Co. Ltd - Advanced Valuation Insights
This section examines the relationship between VitaSpring Biomedical Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1842.50 |
| Latest Market Cap to Assets Ratio | 127.59 |
| Asset Growth Rate (YoY) | 0.0% |
| Total Assets | $765.95K |
| Market Capitalization | $97.73 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values VitaSpring Biomedical Co. Ltd's assets at a significant premium ( 127.59x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: VitaSpring Biomedical Co. Ltd's assets decreased by 0.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for VitaSpring Biomedical Co. Ltd (2017–2026)
The table below shows the annual total assets of VitaSpring Biomedical Co. Ltd from 2017 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-01-31 | $765.95K | 0.00% |
| 2023-01-31 | $765.95K | -78.75% |
| 2022-01-31 | $3.60 Million | +1802.91% |
| 2021-01-31 | $189.40K | -- |
| 2020-01-31 | $0.00 | -- |
| 2019-01-31 | $11.43K | -11.33% |
| 2018-01-31 | $12.89K | +183.01% |
| 2017-01-31 | $4.55K | -- |